Search results: (10000)
News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
News Hemophilia and Intensive Physical Activity Are Not Mutually Exclusive − Case Report of a Top Athlete
Traditionally, many doctors have been reluctant to allow men with hemophilia to engage in more intense physical activity, mainly due to concerns about bleeding caused by overexertion or injury. Today's prophylactic modalities, however, allow for prevention to be set in such a way that the risk of bleeding is significantly reduced. Modern treatment thus brings hope for hemophiliacs to participate in some sports that were previously not recommended. In addition to effective prophylaxis, appropriate training activities, developed with the participation of a physiotherapist and sports doctor, are also crucial.
News No deficiency of essential fatty acids in home parenteral nutrition
A Dutch-British study, the results of which were published in the Journal of Parenteral and Enteral Nutrition, addressed the issue of potential deficiency of essential fatty acids in patients using home parenteral nutrition.
News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
News Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis
The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical response of patients who were switched to baricitinib during the study due to an inadequate response to adalimumab.
News Effect of Combination Therapy on Symptoms of Allergic Rhinitis
The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active ingredients, compared to placebo and monotherapies during a 14-day therapy in adult and adolescent patients with allergic rhinitis.
News Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.
News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.
News Can Erdostein Help in Treating Infections Related to Biofilm Formation?
One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?
News Adding Paracetamol to Tramadol to Relieve Early Postoperative Pain After Lumbar Discectomy
A recently published study is likely the first prospective randomized controlled trial comparing the postoperative analgesic efficacy of a tramadol and paracetamol combination versus tramadol alone. Its results favor the combination, with significantly lower pain scores during the first 30 minutes and reduced tramadol consumption within the first 24 hours post-surgery.
News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU
In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.
News Candesartan Could Ameliorate the Cytokine Storm in COVID-19 Infection
Scientists from Bethesda, USA, experimentally found the upregulation of the same genes during COVID-19 infection as with the action of glutamate (simulating aging and Alzheimer's disease) and the normalization of their expression by candesartan. Considering that many of these genes are involved in the cytokine storm in COVID-19, the mentioned results support the hypothesis that sartans − or at least candesartan − could mitigate the cytokine storm in patients with severe COVID-19.
News MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship with multiple sclerosis be? This unusual topic was explored in a publication in the journal Neurosciences.
News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study
At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice
The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
News Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension
Can monotherapy with bimatoprost be sufficiently effective in controlling intraocular pressure in non-responders to previous treatments? This is the question posed by British researchers in the presented study.
News Basic Information on the Spread and Course of COVID-19 Infection in China: What We Know So Far?
Currently, we are experiencing a worldwide outbreak of COVID-19 infection caused by the SARS-CoV-2 virus, with the first cases identified in December 2019 in Wuhan, China. As of March 18, 2020, according to WHO information, the virus has spread to six continents and a total of 179,111 people worldwide were infected with COVID-19, of whom 7,426 have died from the disease. Sharing transparent, valid, and relevant information is one of the cornerstones of the fight to mitigate the impact of this infection. Chinese authors recently published a summary of current knowledge on the epidemiology, clinical manifestations, diagnosis, treatment, and prevention of COVID-19, valid as of March 2, 2020, in the International Journal of Infectious Diseases.
News Importance of pH in Care for Stoma Patients
Maintaining good quality peristomal skin and preventing complications related to the stoma site are integral parts of comprehensive care for patients with stomas. The pH of the skin also plays an important role in this issue, as it can significantly affect the condition of the skin, the development of complications, the quality of life of patients, and consequently impact the economic aspect of stoma care.
News Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation
A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).
News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study
The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.